Male patients with congenital hemop

Male patients with congenital hemophilia with inhibitors who experienced
spontaneous bleeding were eligible for this observational
study if they required treatment with bypassing agents for
at least four bleeding episodes of any type in the prior 3 months
and were prescribed recombinant activated factor VII as first-line
therapy for bleeding episodes (including breakthrough bleeding
with prophylaxis and immune tolerance therapy [ITT]).